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Background

Results

• In clinical trials, switching from tenofovir disoproxil fumarate (TDF) to tenofovir
alafenamide (TAF) containing antiretroviral therapy (ART) maintained viral
suppression in patients living with HIV (PLWH)
• Switching to TAF also improved renal function and bone mineral density, while
negatively influencing serum cholesterol levels
• The efficacy and safety of switching to TAF in a real world setting is unknown

Characteristic
Mean Age, years (range)
Male Sex, n (%)

Objective
• The primary objective of this study was to determine if patients maintain viral
suppression after switching from TDF to TAF
• The secondary objective was to assess changes in renal function and serum
cholesterol levels

Methods

Table 2: Changes in Renal Function

Table 1: Demographics (n=110)
Result

Renal function
measurement

50 (24 – 77)

Caucasian

38 (34.5)

Hispanic

6 (5.5)

Asian

2 (1.8)

Change

p-Value

104.0

102.5

-1.0

0.82

*Median values reported

Race, n (%)
64 (58.2)

Post-switch

Creatinine Clearance
(mL/min)

80 (72.7)

African American

Pre-switch

Table 3: Changes in Serum Cholesterol Values
Serum cholesterol
measurement

Pre-switch

Post-switch

Change

p-Value

Total Cholesterol (mg/dL)

173.8

195.0

12.5

< 0.01

Median Time with HIV, years (range)

12 (2 – 34)

LDL-C (mg/dL)

98.6

112.1

8.2

< 0.01

• A retrospective chart review of 110 patients switching from a TDF to TAF based
antiretroviral therapy

Median Time on ART, years (range)

8 (1 – 29)

HDL-C (mg/dL)

51.0

55.8

3.0

< 0.01

• Subjects were HIV positive, on TDF based therapy for at least one year, and virally
suppressed during the year prior to switching

Median CD4 Count at Switch,
copies/mL (range)

Triglycerides (mg/dL)

103.5

109.5

4.0

0.28

Total Cholesterol to
HDL-C Ratio

3.5

3.5

0.1

0.25

ASCVD Risk Scores

6.9

8.1

0.4

< 0.01

• Viral suppression was defined as two consecutive HIV viral load measurements
< 200 copies/mL and no values > 200 copies/mL
• To asses the primary endpoint viral load measurements were analyzed one year
after switching for each patient
• To asses renal function and cholesterol changes, creatinine clearance, total
cholesterol, LDL-C, HDL-C, and triglyceride levels were analyzed for each patient
one year before and after switching
• ASCVD risk scores were calculated for eligible patients at the time of their ART
switch and again 6-12 months after the switch for comparison
• ASCVD scores were calculated using the 2018 American College of
Cardiology/American Heart Association guidelines on treating blood cholesterol

Limitations
• The single centered study design could limit the external validity of the results
• Omissions or inaccuracies in medical records could have influenced study results
• The small sample size may not be representative of the entire population of PLWH

Figure 1: Patients with Viral Load
Data After Switching
Viral Load Measured
Viral Load Not Measured

627.5 (138.0 – 1,401.0)

Figure 2: Patients Maintaining
Viral Suppression After Switching
Maintained Supression
Viral Load > 200 copies/mL

1%

12%

*Median values reported

Conclusions
• PLWH in this study maintained viral suppression when switching from a TDF to TAF
based ART and did not experience significant change in renal function
• Patients did however, experience significant increases in total cholesterol, LDL-C,
and HDL-C from baseline measurements

88%

99%

• Changes in cholesterol led to significant increases in ASCVD scores
• The clinical implications of cholesterol and ASCVD changes are unclear, but could
increase in the number of patients requiring statin therapy
• Additional studies are necessary to determine the causes of cholesterol changes in
patients switching to TAF

